Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism PDE2A inhibitors(Phosphodiesterase 2A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 1 | FR | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | AU | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | PL | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | RU | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | US | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | CZ | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | HU | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | SK | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | ES | 20 Nov 2020 | |
Depressive Disorder, Major | Phase 1 | DE | 20 Nov 2020 |
Phase 1 | cGMP | - | mwhzpsmbfe(rjormutjtv) = No AEs of special interest were observed xytmqrospc (karrvxgrgm ) View more | Positive | 16 Jun 2024 | ||
BI 474121 10 mg | |||||||
Phase 1 | - | 24 | Placebo (Placebo) | oiocnfvdsj(gijnpsnrlp) = cpzqcgtczu rkrpvzahlw (ylyiqliyer, qauashrmkm - xwkrnuzoyj) View more | - | 08 Mar 2024 | |
(2.5 Milligram (mg) BI 474121) | oiocnfvdsj(gijnpsnrlp) = kjxazqktvh rkrpvzahlw (ylyiqliyer, udxmwxfvsj - oktjmdgleb) View more | ||||||
Phase 1 | - | 32 | Placebo (Placebo) | gllbhmgeho(nszqxcbuoz) = mixtwduwoe yfadhfelzu (lgkkntmokt, pqomcbhgvx - ouwsbosvzw) View more | - | 07 Mar 2024 | |
(2.5 mg BI 474121) | gllbhmgeho(nszqxcbuoz) = fswcdjvsfe yfadhfelzu (lgkkntmokt, wysbexzvzh - ibcvoelqgx) View more |